CIK 0001754068
- Non-accelerated filer
- Smaller reporting company
Kalaris Therapeutics, Inc.
Sign in to watch- Ticker
- KLRS
- Exchange
- Nasdaq
- Industry
- Biological Products, (No Diagnostic Substances)
- FY end
- Dec 31
- Incorporated
- DE
- Entity type
- Operating
- EIN
- 831971007
- Phone
- +1 650-249-2727
- Business address
- 400 CONNELL DRIVE, SUITE 5500, BERKELEY HEIGHTS, NJ, 07922
- Former names
- Allovir, Inc., ViraCyte, Inc.
- 4 Open-market sale Director sold 12,196 shares at an average $24.80 ($302,455)
- 4 Open-market sale Director sold 2,200 shares at $24.78 ($54,511)
- 4 Open-market sale Director sold 13,592 shares at an average $24.80 ($337,045)
- 4 Open-market sale Atillasoy Ercem sold 1,514 shares at $24.23 ($36,690)
- 4 Open-market sale Chief Medical Officer sold 18,689 shares at an average $23.91 ($446,862)
- 4 Open-market sale Chief Commercial Officer sold 16,584 shares at an average $25.14 ($416,906)
- 4 Open-market sale Chief Medical Officer sold 3,750 shares at $24.12 ($90,432)
- 4 Open-market sale Chief Commercial Officer sold 53,051 shares at an average $26.57 ($1,409,646)
- 4 Open-market sale Chief Medical Officer sold 40,548 shares at an average $22.11 ($896,685)
- 4 Derivatives Options or other derivatives
- 4 Derivatives Options or other derivatives
- 4 Derivatives Options or other derivatives
- 4 Gift Director gave 818,663 shares (gift)
- 4 Derivatives Options or other derivatives
- 4 Derivatives Options or other derivatives
- 4 Derivatives Options or other derivatives
- 4 Grant or award Chief Executive Officer acquired 200,000 shares (grant or award)
- 4 Open-market sale Chief Scientific Officer sold 150,000 shares at $22.75 ($3,412,500)
- 4 Open-market sale Chief Medical Officer sold 3,750 shares at $25.97 ($97,394)
- 4 Open-market sale Chief Scientific Officer sold 3,025 shares at $30.00 ($90,751)
Page 14 of 19 · 363 filings